• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Catalyst Pharmaceuticals Inc. (Amendment)

    2/13/24 5:00:59 PM ET
    $CPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CPRX alert in real time by email
    SC 13G/A 1 tv0553-catalystpharmaceutica.htm SCHEDULE 13G/A catalystpharmaceuticalsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 1)*

    Name of issuer:  Catalyst Pharmaceuticals Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  14888U101

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  14888U101

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    185,471

    7.  SOLE DISPOSITIVE POWER

    6,846,796

    8.  SHARED DISPOSITIVE POWER

    273,621

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    7,120,417

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    6.68%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Catalyst Pharmaceuticals Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    355 Alhambra Circle, Suite 801
    Coral Gables, FL 33134

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    14888U101

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $CPRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CPRX

    DatePrice TargetRatingAnalyst
    2/4/2025$28.00Outperform
    Robert W. Baird
    11/18/2024$35.00Overweight
    Stephens
    3/14/2024$27.00Buy
    Citigroup
    3/7/2024$23.00Buy
    BofA Securities
    12/21/2023$30.00Outperform
    Oppenheimer
    8/24/2022$10.00 → $15.50Buy → Neutral
    ROTH Capital
    2/8/2022$9.00 → $12.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CPRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts

      CORAL GABLES, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "the Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel therapies for patients with rare diseases, today announced that it has contributed $100,000 to the American Red Cross to support ongoing relief efforts for communities impacted by Hurricane Helene. "At Catalyst, our commitment to the community is unwavering, particularly in times of crisis," said Richard J. Daly, President and CEO of Catalyst. "We extend our heartfelt sympathies to those affected by Hurricane Helene and are honored to contribute to the

      10/8/24 8:03:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions

      Ms. Alicia Grande, Catalyst's Current CFO, to Retire at the End of 2023 Dr. Steven Miller Promoted to Executive Vice President, Chief Operating and Scientific Officer and Jeffrey Del Carmen Promoted to Executive Vice President, Chief Commercial Officer CORAL GABLES, Fla., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX) today announced the appointment of Michael W. Kalb as its Executive Vice President and Chief Financial Officer, effective on January 1, 2024. Mr. Kalb will report directly to the Company's Chief Executive Officer and will serve as a member of the Company's executive leadership team. Mr. Kalb's distinguished career in

      12/4/23 8:03:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer

      CORAL GABLES, Fla., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced the appointment of Richard J. Daly as its new Chief Executive Officer ("CEO") effective January 1, 2024. Mr. Daly is a seasoned pharmaceutical executive bringing more than three decades of experience to Catalyst. In order to facilitate an orderly transition, Patrick J. McEnany, Founder, Chairman, and CEO, will retire from the CEO position effective December 31, 2023, and at that time will contin

      10/19/23 8:03:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CPRX
    SEC Filings

    See more
    • SEC Form 144 filed by Catalyst Pharmaceuticals Inc.

      144 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

      5/30/25 4:04:22 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Catalyst Pharmaceuticals Inc.

      8-K - CATALYST PHARMACEUTICALS, INC. (0001369568) (Filer)

      5/23/25 4:30:14 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Catalyst Pharmaceuticals Inc.

      144 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

      5/14/25 10:45:34 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CPRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update

      Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase FIRDAPSE® and AGAMREE® Drive Sustained Organic Growth, Underscoring Execution Strength Reaffirms Full-Year 2025 Total Revenue Guidance Provided Earlier This Year of Between $545 Million and $565 MillionStrengthens Balance Sheet with Cash and Cash Equivalents of $580.7 Million and No Debt as of March 31, 2025 Conference Call and Webcast to be Held on May 8, 2025, at 8:30 AM ET CORAL GABLES, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), today reported f

      5/7/25 4:14:54 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025

      CORAL GABLES, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming BofA Securities Health Care Conference 2025 on Wednesday, May 14, 2025, at the Encore Hotel, Las Vegas, Nevada. Presentation Details:Date: Wednesday, May 14, 2025Time: 8:00 am PTWebcast Link The webcast will be ava

      4/30/25 8:03:00 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025

      CORAL GABLES, Fla., April 22, 2025 (GLOBE NEWSWIRE) --  Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its first quarter 2025 financial results after the market close on Wednesday, May 7, 2025. Catalyst's management team will host a conference call and webcast on Thursday, May 8, 2025, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Conference Call & Webcast DetailsDate: Time:   US/Canada Dial-in Number:Interna

      4/22/25 8:02:59 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CPRX
    Financials

    Live finance-specific insights

    See more

    $CPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update

      Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase FIRDAPSE® and AGAMREE® Drive Sustained Organic Growth, Underscoring Execution Strength Reaffirms Full-Year 2025 Total Revenue Guidance Provided Earlier This Year of Between $545 Million and $565 MillionStrengthens Balance Sheet with Cash and Cash Equivalents of $580.7 Million and No Debt as of March 31, 2025 Conference Call and Webcast to be Held on May 8, 2025, at 8:30 AM ET CORAL GABLES, Fla., May 07, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), today reported f

      5/7/25 4:14:54 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025

      CORAL GABLES, Fla., April 22, 2025 (GLOBE NEWSWIRE) --  Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its first quarter 2025 financial results after the market close on Wednesday, May 7, 2025. Catalyst's management team will host a conference call and webcast on Thursday, May 8, 2025, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Conference Call & Webcast DetailsDate: Time:   US/Canada Dial-in Number:Interna

      4/22/25 8:02:59 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Full Year 2024 Total Revenues of $491.7 Million, Marking Another Year of Record Growth Full Year 2024 Total Revenues Grew 23.5% YoY, Driven by Strong Commercial Performance Q4 2024 Net Product Revenue of $141.8 Million, Fueled by Sustained Organic Growth of FIRDAPSE® and Continued Market Adoption of AGAMREE® Pursuing Strategic Investments to Expand Market Presence and Accelerate Growth Full Year 2025 Total Revenues Expected to be Between $545 Million and $565 Million, Reflecting Confidence in Continued Growth Momentum Conference Call and Webcast to be Held on February 27, 2025, at 8:30 AM ET CORAL GABLES, Fla., Feb

      2/26/25 4:13:25 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Med. & Reg. Officer Ingenito Gary exercised 244,000 shares at a strike of $3.64 and sold $5,775,720 worth of shares (244,000 units at $23.67) (SEC Form 4)

      4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)

      5/15/25 5:00:41 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Med. & Reg. Officer Ingenito Gary exercised 225,000 shares at a strike of $2.24 and sold $4,894,610 worth of shares (225,000 units at $21.75) (SEC Form 4)

      4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)

      3/7/25 5:00:21 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Compliance/Legal Officer Elsbernd Brian exercised 62,525 shares at a strike of $2.24 and sold $1,446,933 worth of shares (62,975 units at $22.98) (SEC Form 4)

      4 - CATALYST PHARMACEUTICALS, INC. (0001369568) (Issuer)

      3/5/25 5:00:39 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Catalyst Pharma with a new price target

      Robert W. Baird initiated coverage of Catalyst Pharma with a rating of Outperform and set a new price target of $28.00

      2/4/25 7:01:07 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stephens initiated coverage on Catalyst Pharma with a new price target

      Stephens initiated coverage of Catalyst Pharma with a rating of Overweight and set a new price target of $35.00

      11/18/24 8:40:25 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup initiated coverage on Catalyst Pharma with a new price target

      Citigroup initiated coverage of Catalyst Pharma with a rating of Buy and set a new price target of $27.00

      3/14/24 7:36:28 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Catalyst Pharmaceuticals Inc.

      SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

      11/14/24 9:55:56 AM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Catalyst Pharmaceuticals Inc.

      SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

      10/18/24 3:31:27 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Catalyst Pharmaceuticals Inc.

      SC 13G/A - CATALYST PHARMACEUTICALS, INC. (0001369568) (Subject)

      10/17/24 12:14:52 PM ET
      $CPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care